LITTLE FALLS, N.J., June 4 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. (NYSE: CMN) reported a 109% increase in net income to $4,183,000, or $0.25 per diluted share, on a 3.5% increase in sales to a record $66,431,000 for the third quarter ended April 30, 2009. This compares with net income of $2,001,000, or $0.12 per diluted share (including costs of $0.03 related to the resignation of our former President), on sales of $64,178,000 for the third quarter ended April 30, 2008. For the nine months ended April 30, 2009, the Company reported an 85% increase in net income to $11,290,000, or $0.69 per diluted share (inclusive of $0.02 of expenses related to the relocation of its Dutch manufacturing operations to the United States), on a 4.4% increase in sales to $193,257,000. This compares with net income of $6,097,000, or $0.37 per diluted share (including costs of $0.03 related to the resignation of our former President), on sales of $185,093,000 for the nine months ended April 30, 2008.
Andrew Krakauer, Cantel's President and CEO stated, "We are very pleased to have delivered another quarter of substantial earnings growth and our strongest quarterly performance of the past few years despite the worldwide economic slowdown. Cantel demonstrated sales growth in all reporting segments except for an expected decline in lower margin dialysate concentrate shipments in our Dialysis segment."
Krakauer added, "While all our businesses performed well, operating income in our Endoscope Reprocessing, Dialysis, and Water Purification and Filtration units was substantially ahead of last year, aided by strong sales of consumables, including disinfectants, sterilants and an increase in service revenue. Additionally, the positive performance was helped by our active cost reduction and margin improvement programs, the effectiveness of price inc
|SOURCE Cantel Medical Corp.|
Copyright©2009 PR Newswire.
All rights reserved